Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 710 vs Infliximab in Rheumatoid Arthritis
NCT02937701Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of infliximab in rheumatoid arthritis (RA) (2 arms), sponsored by Amgen. Primary endpoint: American College of Rheumatology 20% Response at 22 weeks. Started Oct 2016; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02937701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937701.